Eli Lilly's new diabetes drug continues to show promise as an obesity treatment


Eli Lilly continues to work on commercializing its strong innovation pipeline, which is a key reason the CNBC Investing Club owns the stock.

Source link

Leave A Reply

Your email address will not be published.

error: Content is protected !!